AI assistant
Beta Bionics, Inc. — Director's Dealing 2026
Jan 6, 2026
32351_dirs_2026-01-05_2bed9fbc-1642-4f9f-badc-8b1d198403f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2026-01-02
Reporting Person: Mensinger Mike (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-02 | Common Stock | S | 7200 | $29.56 | Disposed | 83552 | Direct |
| 2026-01-02 | Common Stock | S | 600 | $30.1969 | Disposed | 82952 | Direct |
Footnotes
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.
F2: The weighted average sale price for the transaction reported was $29.56 and the range of prices were between $29.05 and $30.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $30.1969 and the range of prices were between $30.10 and $30.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.